Skip to main content
Advicenne logo

Advicenne — Investor Relations & Filings

Ticker · ALDVI ISIN · FR0013296746 LEI · 969500YT5VMEYAYODW34 PA Manufacturing
Open in API
Filings indexed 259 across all filing types
Latest filing 2019-11-15 Board/Management Inform…
Country FR France
Listing PA ALDVI

About Advicenne

https://advicenne.com

Advicenne is a specialty pharmaceutical company dedicated to developing and commercializing treatments for rare renal diseases. The company focuses on addressing unmet medical needs in nephrology for both children and adults. Its lead product, Sibnayal®, is an approved treatment for distal Renal Tubular Acidosis (dRTA). Advicenne is committed to improving the lives of patients with rare kidney conditions by developing therapeutics, including pediatric-friendly formulations, suitable for patients of all ages.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Board/Management Information Classification · 1% confidence The document is a press release dated November 15, 2019, announcing the company's intention to appoint Dr. David Horn Solomon as Chairman of the Board, pending approval at an upcoming Ordinary General Meeting (Assemblée générale ordinaire) on December 20, 2019. This announcement concerns a change in senior governance structure (Board of Directors composition). This directly aligns with the definition of 'Board/Management Information' (MANG), which covers announcements of changes in the company's board of directors or senior management. It is not a full financial report (10-K, IR), an earnings release (ER), or a proxy statement (PSI), but a specific management/governance update.
2019-11-15 French
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 1% confidence The document is titled "Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social" (Monthly information relating to the total number of voting rights and shares comprising the share capital). It explicitly cites French regulations (Code de commerce and AMF General Regulation) and provides a table detailing the number of shares and total voting rights (gross and net) as of October 31, 2019. This content directly relates to reporting changes in share capital structure and voting rights, which aligns best with the 'Share Issue/Capital Change' category (SHA) or potentially a general regulatory filing (RNS). However, since it specifically details the total number of shares and voting rights, SHA is the most precise fit among the defined categories, as it concerns the capital structure.
2019-11-13 French
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release dated November 13, 2019, announcing that the company Advicenne received an award ("Palme d'Oc") at a regional gala. It discusses the company's drug development pipeline (ADV7103) for rare diseases and includes standard forward-looking statements and contact information. This type of announcement, celebrating an award or general corporate news that doesn't fit specific financial reporting categories (like 10-K, ER, or DIV), is best classified as a general Regulatory Filing or Announcement. Since it is not a formal financial report, a management discussion, a proxy statement, or an earnings release, the most appropriate fallback category is Regulatory Filings (RNS), as it is a general corporate communication released to the public/market.
2019-11-13 French
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release dated October 28, 2019, announcing that Advicenne presented additional efficacy data for its drug candidate ADV7103 at the International Pediatric Nephrology Association (IPNA) congress. It details clinical results (plasma bicarbonate, hypocitraturia) and includes quotes from the CEO and Scientific Council Chairman. The final quote from the CEO states, 'These additional results will be added to the registration file during the procedure.' This indicates the communication is an update on clinical trial progress and data presentation, rather than a formal regulatory filing like a 10-K, a comprehensive Interim Report (IR), or a standalone Audit Report (AR). It is a general corporate announcement regarding scientific progress and data dissemination, which fits best under the general 'Regulatory Filings' (RNS) category as a press release detailing scientific/clinical updates, or potentially an Investor Presentation (IP) if it were the presentation itself, but since it's a press release *about* the presentation, RNS is the most appropriate general category for non-standard announcements, or potentially ER if it were summarizing financial results, which it is not. Given the focus on clinical data presentation at a conference, RNS serves as the best fit among the provided options for a general corporate/scientific update press release.
2019-10-28 French
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document is a press release dated October 28, 2019, announcing the presentation of efficacy data for the drug candidate ADV7103 at a medical congress (IPNA). It details clinical study results, quotes management, and includes standard 'About' and 'Forward-Looking Statements' sections typical of corporate news releases regarding clinical progress. This type of announcement, focusing on clinical trial updates and scientific presentations rather than formal financial reporting (like 10-K or IR) or management changes (MANG), is best classified as a general corporate announcement. Since it is not a formal regulatory filing like a 10-K, nor a specific financial report, and it is not announcing a dividend, capital change, or director dealing, the most appropriate category is the general 'Regulatory Filings' fallback (RNS), as it is a public disclosure of material business information, often disseminated via regulatory news services, even if the core content is scientific data presentation.
2019-10-28 English
Inside Information / News release on accounts, results
Interim / Quarterly Report Classification · 1% confidence The document is a press release titled 'Advicenne Presents 2019 Half-Year Financial Report and Confirms Financial Outlook'. It contains substantive financial data, including income statements, balance sheets, and cash flow statements for the six-month period ending June 30, 2019. While it is presented as a press release, it provides the actual financial results and analysis for an interim period, fitting the definition of an Interim/Quarterly Report (IR) rather than just an announcement of a report (RPA). H2 2019
2019-09-23 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.